Trial Profile
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Access the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Single Ascending Dose Administration to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Balcinrenone (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 12 Feb 2018 Results assessing clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD997 in D6400C00001 and D6400C0004 study, published in the British Journal of Clinical Pharmacology
- 24 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov